Abstracts Archive - Page 1857 of 2425 - ACR Meeting Abstracts

Abstract Number: 2953 • 2014 ACR/ARHP Annual Meeting
International Immunochip Study in the Idiopathic Inflammatory Myopathies Identifies Novel Susceptibility Loci and Confirms HLA As Strongest Genetic Risk Factor
Simon Rothwell¹, Robert G. Cooper², Ingrid E. Lundberg³, Frederick W. Miller⁴, Peter K. Gregersen⁵, Jiri Vencovsky⁶, Katalin Danko⁷, Lucy R Wedderburn⁸, Vidya Limaye⁹, Albert Selva O'Callaghan¹⁰, Michael G. Hanna¹¹, Pedro Machado¹¹, Lauren M. Pachman¹², Ann M. Reed¹³, Lisa G. Rider⁴, Joanna Cobb¹, Hazel Platt¹⁴, Øyvind Molberg¹⁵, Olivier Benveniste¹⁶, Pernille Mathiesen¹⁷, Timothy Radstake¹⁸, Andrea Doria¹⁹, Jan De Bleecker²⁰, Boel De Paepe²¹, Britta Maurer²², William E. Ollier¹⁴, Leonid Padyukov³, Terrance P. O'Hanlon⁴, Annette Lee²³, Hector Chinoy¹ and Janine Lamb¹⁴, ¹Centre for Genetics and Genomics, Arthritis Research UK, University of Manchester, Manchester, United Kingdom, ²MRC/ARUK Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, ³Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁵The Feinstein Institute for Medical Research, Manhasset, NY, ⁶Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁷University of Debrecen, University of Debrecen, Debrecan, Hungary, ⁸Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁹Royal Adelaide Hospital, Adelaide, Australia, ¹⁰Vall d'Hebron General Hospital, Barcelona, Spain, ¹¹MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, United Kingdom, ¹²Cure JM Myositis Center, Ann & Robert H. Lurie Children's Hospital of Chicago Research Center, Chicago, IL, ¹³Rheumatology, Mayo Clinic, Rochester, MN, ¹⁴Centre for Integrated Genomic Medical Research, University of Manchester, Manchester, United Kingdom, ¹⁵Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ¹⁶Internal Medecine Dpt 1, Pitié-Salpêtrière Hospital, APHP, Paris, France, ¹⁷Paediatric Department, Holbaek University Hospital, Holbaek, Denmark, ¹⁸University Medical Center Utrecht, Utrecht, Netherlands, ¹⁹Department of Medicine - DIMED, University of Padova, Padova, Italy, ²⁰University of Ghent, Ghent, Belgium, ²¹Neuromuscular Reference Center, University of Ghent, Ghent, Belgium, ²²Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²³Genomics & Human Genetics, Feinstein Institute Med Rsch, Manhasset, NY
Background/Purpose: The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of rare autoimmune diseases characterised by muscle weakness and extramuscular manifestations such as skin rashes…
Abstract Number: 2954 • 2014 ACR/ARHP Annual Meeting
The Amino Acid Positions 11, 13 and 26 of HLA-DR Beta Chain 1 Explain the Majority of the Association Between Systemic Lupus Erythematosus and the Major Histocompatibility Complex Locus
Kwangwoo Kim^1,2,3, So-Young Bang⁴, Hye-Soon Lee⁴, Yukinori Okada^2,3,5, Woei-Yuh Saw⁶, Paul IW. de Bakker^2,3,7, Yik-Ying Teo^6,8, Soumya Raychaudhuri^2,9,10 and Sang-Cheol Bae¹, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ³Broad Institute, Cambridge, MA, ⁴Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁵Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ⁶National University of Singapore, Singapore, Singapore, ⁷Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, ⁸Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore, ⁹Broad Institute of MIT and Harvard, Cambridge, MA, ¹⁰Manchester Academic Health Sciences Centre, Manchester, United Kingdom
Background/Purpose: Genetic association of the major histocompatibility complex (MHC) locus is well-established in systemic lupus erythematosus (SLE), but the causal functional variants in this region…
Abstract Number: 2955 • 2014 ACR/ARHP Annual Meeting
The Impact of Northern European Ancestry and Susceptibility Loci on the Risk of Lupus Nephritis
Sarah French¹, Kimberly E. Taylor², Sharon A. Chung¹, Joanne Nitiham³, Michelle Petri⁴, Peter K. Gregersen⁵, Ward Ortmann⁶, Annette T. Lee⁷, Timothy W. Behrens⁶, Susan Manzi⁸, F. Yesim Demirci⁹, M. Ilyas Kamboh¹⁰, Robert R. Graham⁶, Michael F. Seldin¹¹ and Lindsey A. Criswell³, ¹School of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ²Department of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ³Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁶ITGR Human Genetics, Genentech, Inc., South San Francisco, CA, ⁷Genomics & Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁸Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰Human Genetics, University of Pittsburgh, Pittsburgh, PA, ¹¹Department of Biochemistry and Molecular Medicine, University of California, Davis, Davis, CA
Background/Purpose Lupus nephritis (LN) has a higher prevalence among African Americans, Hispanics, and Asians compared to Caucasians. Significant differences in SLE severity also exist within…
Abstract Number: 2915 • 2014 ACR/ARHP Annual Meeting
Effects of Methotrexate on Anti-TNF Treatment in Rheumatoid Arthritis: An in-Depth Analysis of a Prospective Observational Study with Adalimumab
Marc Schmalzing¹, Frank Behrens^2,3, Eva C. Scharbatke¹, Michaela Koehm^3,4, Bianca Wittig⁵, Gerd Greger⁶, Harald Burkhardt^2,7 and Hans-Peter Tony⁸, ¹Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ²Rheumatology, Goethe-University Frankfurt, Frankfurt, Germany, ³Clinical Research, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, ⁴Rheumatology, Goethe-University Frankfurt, Frankfurt/Main, Germany, ⁵Abbvie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁶AbbVie GmbH & Co KG, Wiesbaden, Germany, ⁷Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, ⁸Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany
Background/Purpose Methotrexate (MTX) is currently the most frequently used drug in the treatment of rheumatoid arthritis (RA). MTX co-medication can improve the therapeutic benefit of…
Abstract Number: 2916 • 2014 ACR/ARHP Annual Meeting
Effects of Exercise on Body Composition, Cardiovascular Fitness, Muscle Strength, and Cognition in Patients with Rheumatoid Arthritis: A Randomised Controlled Trial of a Patient-Specific Exercise Programme
Maha Azeez¹, Ciara Clancy², Tom O'Dwyer³, Fiona Wilson³ and Gaye Cunnane⁴, ¹Rheumatology, St James's Hospital and Trinity College Dublin, Dublin, Ireland, ²Department of Physiotherapy, Trinity College Dublin, Dublin, Ireland, ³Physiotherapy, Trinity College Dublin, Dublin, Ireland, ⁴Dept of Rheumatology, St James's Hospital and Trinity College Dublin, Dublin, Ireland
Background/Purpose Rheumatoid Arthritis (RA) patients have lower levels of physical activity compared to their non-RA counterparts. Large proportions of patients with RA are overweight or…
Abstract Number: 2917 • 2014 ACR/ARHP Annual Meeting
Inhibition of PAD4 Activity and the Formation of Neutrophil Extracellular Traps Via PTPN22, but Not Its Rheumatoid Arthritis-Prone W620 Variant
I-Cheng Ho¹, Hui-Hsin Chang¹, Nishant Dwivedi¹, Hsiao-Wei Tsao¹ and Anthony Nicholas², ¹Medicine, Brigham and Women's Hospital, Boston, MA, ²Neurology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: One unique feature of rheumatoid arthritis (RA) is the presence of anti-citrullinated protein antibody (ACPA). Protein citrullination, a process mediated by peptidyl arginine deiminases,…
Abstract Number: 2918 • 2014 ACR/ARHP Annual Meeting
Fine-Mapping Major Histocompatibility Complex Associations in ACPA-Positive Rheumatoid Arthritis Identified Shared HLA Amino Acid Polymorphisms in Asian and European Populations
Yukinori Okada¹, Kwangwoo Kim², Buhm Han³, Nisha E. Pillai⁴, Rick T-H. Ong⁴, Woei-Yuh Saw⁴, Ma Luo⁵, Lei Jiang⁶, Jian Yin⁶, So-Young Bang⁷, Hye-Soon Lee⁷, Matthew A. Brown⁸, Sang-Cheol Bae², Huji Xu⁹, Yik-Ying Teo⁴, Paul IW. de Bakker¹⁰ and Soumya Raychaudhuri³, ¹Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁴National University of Singapore, Singapore, Singapore, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶The Second Military Medical University, Shanghai, China, ⁷Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ⁸University of Queensland Diamantina Institute, Brisbane, Australia, ⁹Shanghai Changzheng Hospital, Shanghai, China, ¹⁰Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) risk is strongly associated with variations within the major histocompatibility complex (MHC) region, and in particular to HLA-DRB1 alleles. We aimed…
Abstract Number: 2919 • 2014 ACR/ARHP Annual Meeting
The Novel Rheumatoid Arthritis (RA) Risk Gene, LBH, Is Regulated By TGFß and PDGF and Modulates Cell Growth in Fibroblast-like Synoviocytes
Anna-Karin Ekwall¹, Deepa Hammaker², John W. Whitaker³, William Bugbee⁴, Wei Wang⁵ and Gary S. Firestein⁶, ¹Medicine, UC San Diego, La Jolla, CA, ²Medicine, University of California San Diego, La Jolla, CA, ³860 island ave, UCSD, San Diego, CA, ⁴Orthopaedics, Scripps Clinic, La Jolla, CA, ⁵Chemistry, UCSD, La Jolla, CA, ⁶Division of Rheumatology, Allergy and Immunology, University of California at San Diego School of Medicine, La Jolla, CA
Background/Purpose: RA fibroblast-like synoviocytes (FLS) display an aggressive phenotype, such as increased cytokine production and cell growth. Currently no therapeutics specifically target FLS. To this…
Abstract Number: 2921 • 2014 ACR/ARHP Annual Meeting
Contraceptive Factors Are Associated with Serum Antibodies to Citrullinated Protein Antigens in Women at Elevated Risk for Future Rheumatoid Arthritis
Sonia Khatter¹, Mark C. Parish², Marie L. Feser², Jason R. Kolfenbach², Ryan W. Gan³, Michael H. Weisman⁴, James R. O'Dell⁵, Ted R. Mikuls⁶, Richard M. Keating⁷, Peter K. Gregersen⁸, Jane H. Buckner⁹, V. Michael Holers¹⁰, Kevin D. Deane², Jill M. Norris³ and M. Kristen Demoruelle², ¹University of Colorado School of Medicine, Aurora, CO, ²Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ³Epidemiology, Colorado School of Public Health, Aurora, CO, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁶Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁷Division of Rheumatology, Scripps Clinic, La Jolla, CA, ⁸Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁹Benaroya Research Institute at Virginia Mason, Seattle, WA, ¹⁰Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: The preclinical period of rheumatoid arthritis (RA) development is characterized by elevations of serum RA-related autoantibodies (Abs) including Abs to citrullinated protein antigens (ACPA)…
Abstract Number: 2922 • 2014 ACR/ARHP Annual Meeting
Association of Single Nucleotide Polymorphisms of PADI4 Gene with Susceptibility to Rheumatoid Arthritis-Related Lung Disease
Seong-Wook Kang¹, Seung-Taek Song¹, Song Soo Kim², Ji Young Kim¹, So Young Lee¹, Su-Jin Yoo³, In-Seol Yoo¹, Jinhyun Kim¹ and Seung-Cheol Shim¹, ¹Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea, ²Department of Radiology, Chungnam National University School of Medicine, Daejeon, South Korea, ³Rheumatology, Chungnam National University School of Medicine, Daejeon, South Korea
Background/Purpose Rheumatoid arthritis (RA) causes a myriad of pulmonary complications, including bronchiolitis and bronchiectasis, pleuritis, and interstitial lung disease (ILD). Recently, several studies have shown…
Abstract Number: 2923 • 2014 ACR/ARHP Annual Meeting
Protein Quantification Using Mass Spectrometry Methods to Predict Response to Abatacept and Methotrexate Combination Therapy in Rheumatoid Arthritis
A Obry^1,2, P Cosette², T Lequerré^1,3, Maria-Antonietta d'Agostino⁴, C Gaillez⁵, M Le Bars⁶ and O Vittecoq^1,3, ¹Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ²UMR 6270 CNRS, PISSARO Proteomic Facility, IRIB, Normandy University, University of Rouen, Rouen, France, ³Department of Rheumatology, Rouen University Hospital, Rouen, France, ⁴AP-HP Ambroise Paré Hospital, Boulogne-Billancourt, France, ⁵Formerly of Bristol-Myers Squibb, Rueil-Malmaison, France, ⁶Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: Targeted biologic therapies with different mechanisms of action are commonly used in RA. Abatacept is a recombinant fusion protein that inhibits T-cell co-stimulatory molecules…
Abstract Number: 2924 • 2014 ACR/ARHP Annual Meeting
Clinical Utility of Random Anti-TNF Drug Level Testing and Measurement of Anti-Drug Antibodies on Long-Term Treatment Response in Rheumatoid Arthritis
Meghna Jani¹, Hector Chinoy^1,2, Richard B. Warren³, Christopher E.M Griffiths³, Ann W. Morgan⁴, Anthony G. Wilson⁵, Kimme L. Hyrich¹, John Isaacs⁶, Darren Plant^1,2 and Anne Barton^1,7, ¹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ³Dermatology Centre, University of Manchester, Manchester, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Dublin, Ireland, ⁶Institute of Cellular Medicine, University of Newcastle, Newcastle, United Kingdom, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose Up to 40% of RA patients on anti-TNF treatment fail to respond either due to primary inefficacy or loss of response. One explanation is…
Abstract Number: 2925 • 2014 ACR/ARHP Annual Meeting
Serum MMP-3 Predicts a Subgroup with No Radiographic Progression in Rheumatoid Arthritis Patients with Low-Dose Methotrexate (MTX) Monotherapy
Kazuko Shiozawa¹, Takashi Yamane², Miki Murata¹, Chihiro Tanaka¹, Noriaki Yo², Ryosuke Yoshihara¹, Yasushi Tanaka¹, Ken Tsumiyama³ and Shunichi Shiozawa⁴, ¹The Rheumatic Diseases Center, Kohnan Kakogawa Hospital, Kakogawa, Japan, ²Kohnan Kakogawa Hospital, Kakogawa, Japan, ³Department of Rheumatology, Kyushu University Beppu Hospital, Beppu, Japan, ⁴Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: Studies have shown that treating rheumatoid patients with methotrexate (MTX) monotherapy initially and later providing an option to step up to combination therapy produces…
Abstract Number: 2926 • 2014 ACR/ARHP Annual Meeting
Calprotectin Serum Levels Reflect Residual Inflammatory Activity in Patients with Rheumatoid Arthritis and Psoriatic Arthritis on Clinical Remission or Low Disease Activity Undergoing TNF-Antagonists Therapy
Jose Inciarte-Mundo¹, M. Victoria Hernández¹, Sonia Cabrera-Villalba¹, Julio Ramirez¹, Andrea Cuervo¹, Virginia Ruiz-Esquide¹, Azucena González Navarro², Jordi Yagüe³, Juan D. Cañete¹ and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Immunology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ³Immunology Department, Hospital Clinic Barcelona, Barcelona, Spain
Background/Purpose: Calprotectin is a major S100 leucocyte protein, is associated to disease activity in rheumatoid arthritis (RA) and Psoriatic Arthritis (PsA) patients. Calprotectin is a potentially…
Abstract Number: 2927 • 2014 ACR/ARHP Annual Meeting
Baseline Serum Interferon Beta/Alpha Ratio Predicts Response to Tumor Necrosis Factor Alpha Inhibition in Rheumatoid Arthritis
Priyanka Vashisht¹, Jessica M. Dorschner², Mark A. Jensen³, Beverly Chrabot⁴, Theresa Wampler Muskardin⁵, Marlena Kern⁶, Tetrad Investigators⁷, ABCoN Consortium⁸, S. Louis Bridges Jr.^9,10, P.K. Gregersen¹¹ and Timothy B. Niewold², ¹Division of Rheumatology and Department of Immunology, University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Divsion of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁴Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁵Div of Rheumatology, Mayo Clinic, Rochester, MN, ⁶North Shore Univ Hospital, Feinstein Institute for Medical Research, Manhasset, NY, ⁷AL, ⁸NY, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹¹The Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose Response to tumor necrosis factor alpha (TNF-α) inhibition is variable in rheumatoid arthritis (RA). Previous studies have suggested that circulating type I interferon (IFN)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].